GlassScriptPhysician profile
Stephanie Eng
NPI 1851657456
$2,211.09
in general payments reported to CMS, 2019-2025
18 companies · $818 in 2025
The $818 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $358 · 2022: $122 · 2023: $109 · 2024: $804 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,632 · Education: $99.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,631.73 |
| Education | $99.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $586.21 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $473.77 | 2020-2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $242.09 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $191.14 | 2024-2025 | Dupixent |
| Genentech USA, INC. | $108.04 | 2024-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $92.87 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $85.97 | 2025 | Orladeyo |
| Grifols USA, LLC | $68.63 | 2025 | Xembify |
| Kaleo, INC. | $58.05 | 2024 | Auvi-Q |
| Blueprint Medicines Corporation | $56.49 | 2024 | Ayvakit |
| Genzyme Corporation | $49.76 | 2025 | |
| Novartis Pharmaceuticals Corporation | $49.04 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.88 | 2022 | |
| Organon LLC | $25.70 | 2025 | |
| Covis Pharma Gmbh | $25.23 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.92 | 2025 | Cuvitru |
| Pfizer INC. | $15.97 | 2023 | |
| Abbvie INC. | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.